INTERCHANGEABILITY OF PHID-CV10 AND PCV13 IN PRIMARY COURSE SCHEDULES (ID 204)

Session Name
Vaccines - Pneumococcal Vaccines Development
Presenter
  • Amanda J. Leach, Australia
Authors
  • Amanda J. Leach, Australia
  • Nicole Wilson, Australia
  • Jemima Beissbarth, Australia
  • Kim E. Mulholland, Australia
  • Mathuram Santosham, United States of America
  • Peter McIntyre, Australia
  • Paul V. Licciardi, Australia
  • Mark Chatfiled, Australia
  • Victor Oguoma, Australia
  • Jonathan Carapetis, Australia
  • Sue Skull, Australia
  • Heidi Smith-Vaughan, Australia
  • Vicki Krause, Australia
  • Ross Andrews, Australia
  • Peter Morris, Australia
  • Paul Torzillo, Australia

Abstract

Background

In remote communities of northern Australia, we previously demonstrated that the onset of otitis media (OM) in Aboriginal infants was preceded by acquisition of bacterial pathogens that colonise the nasopharynx (NP) soon after birth. We aimed to determine safety and effectiveness of mixed vaccine schedules against early infection due to non-typeable Haemophilus influenzae and Streptococcus pneumoniae.

Methods

In an open-label controlled trial, we randomised (1:1:1) Aboriginal infants at 28 to 38 days of age, to either Prevenar13™ (P, PCV13) at 2-4-6 months of age (_PPP), Synflorix™ (S, PHiD-CV10) at 2-4-6 months (_SSS), or Synflorix at 1-2-4 months plus Prevenar13 at 6 months (SSSP). Primary outcomes (assessor-blinded) were immunogenicity at 7 months of age against pneumococcal serotypes 3, 6A, and 19A, and protein D (GMCs and proportions of infants with IgG > 0·35 µg/mL or > 100 EL.U/mL, respectively). Secondary immunogenicity outcomes at 2 and 4 months are also reported.

Results

A 4-dose early 1-2-4-6 month combination schedule of Synflorix plus Prevenar13 (SSSP) provided superior overall immune protection against serotypes 3, 6A, 19A, and protein D, compared to standard 3-dose 2-4-6 month schedules (_SSS or _PPP).

Conclusions

These vaccines can be combined safely and effectively within this primary schedule, with no evidence of immune suppression.

Hide